SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR)

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype.


Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 

Please refer to this study by its identifier: NCT03713320

Study Sponsor
miRagen Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
Study Director:  Diana M. Escolar, MD, FAAN
Phone:  +1-720-643-5230

Overall Recruitment Status
Active, not recruiting

Study Update
The SOLAR study is ongoing. Patients participating in the study at this time continue to receive treatment and are being evaluated for potential benefits and side effects. The study is not currently enrolling new patients until the results of study data from a mid-study time point are reviewed.  This mid-study review is expected to occur in the second half of 2020. The mid-study data review will provide early insight into the effect of cobomarsen in patients with CTCL and will inform future enrollment into the SOLAR study. 


United States, New York
Rochester Skin Lymphoma Medical Group   
Fairport, New York, United States, 14450

Columbia University Medical Center
New York, New York, United States, 10032

Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065